Combination of Phage Display and Molecular Grafting Generates Highly Specific Tumor‐Targeting Miniproteins
- 13 November 2012
- journal article
- research article
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 51 (52) , 13136-13139
Abstract
Frankenstein′s peptide: The grafting of the binding domain from miniprotein Min-23 into the sunflower trypsin inhibitor (SFTI-I) peptide scaffold (see scheme) preserved its in vitro and in vivo binding specificity and proteolytic stability. The combination of these peptides was shown to be tumor-specific with a good binding affinity for delta-like ligand 4 (Dll4) protein. The use of SFTI-I as a peptide scaffold is ideal for hit-to-lead development.Keywords
This publication has 21 references indexed in Scilit:
- Engineering and Functionalization of the Disulfide‐Constrained Miniprotein Min‐23 as a Scaffold for Diagnostic ApplicationChemMedChem, 2011
- Engineering pro-angiogenic peptides using stable, disulfide-rich cyclic scaffoldsBlood, 2011
- Biotechnology techniques for the development of new tumor specific peptidesMethods, 2011
- Miniproteins as Phage Display-Scaffolds for Clinical ApplicationsMolecules, 2011
- Alternative non-antibody scaffolds for molecular recognitionCurrent Opinion in Biotechnology, 2007
- Potential therapeutic applications of the cyclotides and related cystine knot mini-proteinsExpert Opinion on Investigational Drugs, 2007
- Engineering novel binding proteins from nonimmunoglobulin domainsNature Biotechnology, 2005
- Binding proteins from alternative scaffoldsJournal of Immunological Methods, 2004
- Min-21 and Min-23, the Smallest Peptides That Fold Like a Cystine-Stabilized β-Sheet Motif: Design, Solution Structure, and Thermal StabilityBiochemistry, 1999
- Phage DisplayChemical Reviews, 1997